The Steven Larson Lab: Projects

Pillarsetty Group

My research group is dedicated to the development of novel radiopharmaceuticals for diagnostic and therapeutic applications, and, aiding clinical translation of these novel radiopharmaceuticals to the clinic.

Tumor Targeting and Cell-trafficking Studies of 131I/124I]-FIAU-labeled Genetically Modified Antigen-specific Lymphocytes

Donor T cells are reactive against and effective in adoptive immunotherapy of Epstein-Barr virus (EBV) lymphomas, which develop in some leukemia patients after marrow transplantation. Such T cells have been genetically modified by incorporation of a replication-incompetent vector (NIT) for an inactive mutant nerve growth factor receptor (LNGFR) as an immunoselectable surface marker and a herpes simplex virus thymidine kinase gene (HSV-TK), rendering the cells sensitive to ganciclovir.

Noninvasive Diagnosis and Quantitation of Multi-drug Resistance by PET

Tumor multiple drug resistance (MDR) is defined as the property of cancer cells to resist the action of a large variety of chemically and functionally unrelated substances, including but not limited to chemotherapeutic drugs.

Multi-step Targeting in Radioimmunodiagnosis and Radioimmunotherapy

Monoclonal antibodies and antibody fragments raised against a variety of tumor-specific and tumor-associated epitopes have been labeled with a variety of radioisotopes for tumor imaging by single-photon emission computed tomography (SPECT) and, more recently, for positron emission tomography (PET) and internal radionuclide therapy.